General MedicationsINTRAVENOUSStandard
KHAPZORY
LEVOLEUCOVORIN
Standard Dose
175MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview KHAPZORY is listed in Drugs@FDA under application 211226 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient LEVOLEUCOVORIN Form and strength POWDER;INTRAVENOUS - 175MG/VIAL Sponsor ACROTECH BIOPHARMA Submission history Latest submission status date: 2020-03-03 00:00:00.
Structured Monograph
Clinical summary
Approval overview KHAPZORY is listed in Drugs@FDA under application 211226 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LEVOLEUCOVORIN Form and strength POWDER;INTRAVENOUS - 175MG/VIAL Sponsor ACROTECH BIOPHARMA Submission history Latest submission status date: 2020-03-03 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.